US 12,351,637 B2
Nucleic acid-polypeptide compositions and uses thereof
Andrew John Geall, Carlsbad, CA (US); Venkata Ramana Doppalapudi, San Diego, CA (US); David Sai-Ho Chu, La Jolla, CA (US); Michael Caramian Cochran, La Jolla, CA (US); Rachel Elizabeth Johns, San Diego, CA (US); Palani Balu, Cupertino, CA (US); Rob Burke, Encinitas, CA (US); and Beatrice Diana Darimont, San Diego, CA (US)
Assigned to AVIDITY BIOSCIENCES, INC., San Diego, CA (US)
Filed by Avidity Biosciences, Inc., La Jolla, CA (US)
Filed on May 5, 2021, as Appl. No. 17/308,888.
Application 17/308,888 is a continuation of application No. 17/187,669, filed on Feb. 26, 2021.
Application 17/187,669 is a continuation of application No. 15/476,849, filed on Mar. 31, 2017, abandoned.
Claims priority of provisional application 62/316,919, filed on Apr. 1, 2016.
Prior Publication US 2022/0324984 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01); A61K 47/60 (2017.01); A61K 47/68 (2017.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 16/30 (2006.01); C12N 15/113 (2010.01); C12N 15/88 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 47/60 (2017.08); A61K 47/6807 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); A61K 48/0033 (2013.01); A61K 48/005 (2013.01); A61K 48/0075 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/2851 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); C12N 15/1138 (2013.01); C12N 15/88 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/332 (2013.01); C12N 2310/3513 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/32 (2013.01)] 15 Claims
 
1. An antibody conjugate of Formula (V):
A-C-B   Formula (V)
wherein,
A is an antibody or antigen-binding fragment thereof,
B is a polynucleotide;
C is a polymer;
wherein C is conjugated to a cysteine or lysine residue of A and wherein A-C is conjugated to the 5′ end of a sense strand of B; and
wherein the antibody or antigen-binding fragment thereof binds to a cell surface receptor;
wherein the polynucleotide comprises at least one 2′ modified nucleotide, at least one modified internucleotide linkage, or at least one inverted abasic moiety.